Delivering New Therapies for Thyroid Eye Disease and Beyond


To ensure that our therapies have their greatest impact by always focusing on the patient, and following the science to run impactful and high-quality clinical development. 


Linsitinib is an oral therapy being developed for thyroid eye disease (TED) that will ease the treatment burden for patients, caregivers, and physicians.


We have an experienced team of executives, drug developers, and scientific advisors whose deep expertise and dedication keep them driving for solutions.